ALK and non-small cell lung carcinoma: Similarly, the IMpower130 trial demonstrated that atezolizumab plus carboplatin and nab-paclitaxel significantly improved median OS and PFS in advanced non-squamous NSCLC patients, including those with EGFR/ALK mutations.